Thomas Catinazzo - 09 Mar 2026 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Signature
/s/ Soo-Yeun Lim, as Attorney-in-Fact
Issuer symbol
RLAY
Transactions as of
09 Mar 2026
Net transactions value
-$178,233
Form type
4
Filing time
11 Mar 2026, 16:30:35 UTC
Previous filing
29 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Catinazzo Thomas Chief Financial Officer C/O RELAY THERAPEUTICS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE /s/ Soo-Yeun Lim, as Attorney-in-Fact 11 Mar 2026 0001818261

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Sale $178,233 -17,717 -7.1% $10.06 231,584 09 Mar 2026 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
F2 This transaction was executed in multiple trades at prices ranging from $9.77 to $10.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 Includes 13,075 shares underlying restricted stock units.